The MyVal Transcatheter Heart Valve (THV) System represents a significant advancement in structural heart intervention, addressing complications associated with aortic valve disorders. These conditions are treated through Transcatheter Aortic Valve Replacement (TAVR) or Transcatheter Aortic Valve Implantation (TAVI) procedures.
Our endeavour has always been to innovate ways in which we can keep the heart beating. With growing stresses and lifestyle changes over the decades and centuries, there has been a noticeable surge in heart attacks and other heart conditions
Developed by Meril, the MyVal Transcatheter Heart Valve (THV) enhances precision in minimally invasive aortic valve interventions, enabling effective treatment without open-heart surgery. MyVal’s advanced design and materials prioritize patient outcomes and procedural efficiency.
To meet evolving cardiovascular challenges, Meril developed MyVal as an innovative solution in structural heart interventions, reflecting our commitment to advanced cardiovascular care.
The Product
MyVal is a transcatheter heart valve (THV) designed with precision to optimize outcomes in minimally invasive aortic valve procedures. It supports Transcatheter Aortic Valve Implantation (TAVI), enabling effective treatment without the need for open-heart surgery.
It comes with a hybrid honeycomb cell design concept, a cobalt alloy frame for high radial strength, and an AntiCa+ treated bovine pericardium
It also has an external PET skirting to plug microchannels, and an internal PET sealing cuff for puncture resistance
The MyVal is CE certified and available in various sizes to enhance patient outcomes, particularly with its ease of precision placement during the TAVI procedure.
Clinical studies have demonstrated that the MyVal THV series offers significant advantages over contemporary THV systems, showing low device-related mortality, a reduced incidence of stroke, and a decreased need for permanent pacemakers. Over a six-month study period, the MyVal THV has been well-received by both patients and healthcare providers, establishing its efficacy and safety in structural heart interventions.
